PE20081632A1 - Composiciones de tableta en tableta - Google Patents
Composiciones de tableta en tabletaInfo
- Publication number
- PE20081632A1 PE20081632A1 PE2008000126A PE2008000126A PE20081632A1 PE 20081632 A1 PE20081632 A1 PE 20081632A1 PE 2008000126 A PE2008000126 A PE 2008000126A PE 2008000126 A PE2008000126 A PE 2008000126A PE 20081632 A1 PE20081632 A1 PE 20081632A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- tablet
- amount
- component
- layer
- Prior art date
Links
- 239000007916 tablet composition Substances 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940035811 conjugated estrogen Drugs 0.000 abstract 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 abstract 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA TABLETA CENTRAL QUE COMPRENDE DE 10% A 50% EN PESO DE LA COMPOSICION Y CONTIENE i) UN ESTROGENO CONJUGADO; ii) UN COMPONENTE RELLENADOR/DILUYENTE TAL COMO LACTOSA EN UNA CANTIDAD DE 30% A 85% EN PESO DE LA TABLETA CENTRAL; iii) UN COMPONENTE RELLENADOR/AGLOMERANTE TAL COMO CELULOSA MICROCRISTALINA EN UNA CANTIDAD DE 1% A 30% EN PESO DE LA TABLETA CENTRAL; iv) UN COMPONENTE POLIMERICO DE FORMACION DE GEL HIDROFILICO TAL COMO HIDROXIPROPILMETILCELULOSA EN UNA CANTIDAD DE 1% A 40% EN PESO DE LA TABLETA CENTRAL; Y v) UN COMPONENTE LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE 0.01% A 2% EN PESO DE LA TABLETA CENTRAL; B) UNA CAPA DE TABLETA EXTERIOR QUE COMPRENDE DE 50% A 90% EN PESO DE LA COMPOSICION QUE CONTIENE i) UN MODULADOR DEL RECEPTOR DE ESTROGENO Y AGENTES PROGESTACIONALES TAL COMO ACETATO DE BAZEDOXIFENO O ACETATO DE MEDROXIPROGESTERONA; ii) UN COMPONENTE RELLENADOR/DILUYENTE EN UNA CANTIDAD DE 10% A 80% EN PESO DE LA CAPA DE LA TABLETA EXTERIOR; iii) UN COMPONENTE RELLENADOR/AGLOMERANTE EN UNA CANTIDAD DE 1% A 60% EN PESO DE LA CAPA DE LA TABLETA EXTERIOR; iv) UN COMPONENTE DE POLIMERO DE FORMACION DE GEL HIDROFILICO EN UNA CANTIDAD DE 1% A 70% EN PESO DE LA CAPA DE LA TABLETA EXTERIOR; v) UN COMPONENTE ANTIOXIDANTE TAL COMO ACIDO ASCORBICO EN UNA CANTIDAD DE 0.01% A 4% EN PESO DE LA CAPA DE LA TABLETA EXTERIOR; vi) UN LUBRICANTE EN UNA CANTIDAD DE 0.01% A 2% EN PESO DE LA TABLETA EXTERIOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88480107P | 2007-01-12 | 2007-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081632A1 true PE20081632A1 (es) | 2008-12-10 |
Family
ID=39315069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000126A PE20081632A1 (es) | 2007-01-12 | 2008-01-11 | Composiciones de tableta en tableta |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080175908A1 (es) |
| EP (1) | EP2117518A2 (es) |
| JP (1) | JP2010515758A (es) |
| KR (1) | KR20090104862A (es) |
| CN (1) | CN101631536A (es) |
| AR (1) | AR064875A1 (es) |
| AU (1) | AU2008206476A1 (es) |
| BR (1) | BRPI0806543A2 (es) |
| CL (1) | CL2008000095A1 (es) |
| CO (1) | CO6210806A2 (es) |
| IL (1) | IL199656A0 (es) |
| MX (1) | MX2009007254A (es) |
| PE (1) | PE20081632A1 (es) |
| RU (1) | RU2009125413A (es) |
| TW (1) | TW200836773A (es) |
| WO (1) | WO2008089087A2 (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952338A (zh) | 2005-02-03 | 2022-01-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP3135285B1 (en) | 2008-06-17 | 2018-08-15 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| WO2009158584A1 (en) * | 2008-06-27 | 2009-12-30 | Wyeth | Dual adhesive technology |
| CN105963313A (zh) | 2008-08-04 | 2016-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| KR20190128004A (ko) | 2009-04-06 | 2019-11-13 | 와이어쓰 엘엘씨 | 네라티닙을 이용한 유방암의 치료법 |
| US20110217369A1 (en) * | 2009-09-03 | 2011-09-08 | Ranbaxy Laboratories Limited | Fenofibrate compositions |
| AR078785A1 (es) * | 2009-10-27 | 2011-11-30 | Wyeth Llc | Formulaciones de bazedoxifeno con antioxidantes |
| EP3566697B1 (en) * | 2009-11-09 | 2024-09-11 | Wyeth LLC | Tablet formulations of neratinib maleate |
| EP2498751B1 (en) | 2009-11-09 | 2019-04-03 | Wyeth LLC | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| BR112012012947B8 (pt) * | 2009-11-27 | 2021-05-25 | Genzyme Corp | sal de hemitartarato e composição farmacêutica compreendendo o mesmo |
| US20110280936A1 (en) * | 2010-05-17 | 2011-11-17 | Aptapharma, Inc. | Self Breaking Tablets |
| PE20181177A1 (es) | 2010-12-22 | 2018-07-20 | Purdue Pharma Lp | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| RS54880B1 (sr) | 2011-06-01 | 2016-10-31 | Estetra Sprl | Postupak proizvodnje intermedijarnih proizvoda estetrola |
| WO2012164095A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA2879404A1 (en) | 2012-07-20 | 2014-01-23 | Otsuka Pharmaceutical Co., Ltd. | Tablet having dry-ink film on surface thereof, and ink for inkjet printer |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| WO2015086643A1 (en) * | 2013-12-12 | 2015-06-18 | Donesta Bioscience B.V. | Orally disintegrating solid dosage unit containing an estetrol component |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN104013630B (zh) * | 2014-05-23 | 2018-08-21 | 合肥九研医药科技开发有限公司 | 一种复方醋酸巴多昔芬雌激素组合物 |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| CN104546794A (zh) * | 2015-01-05 | 2015-04-29 | 万特制药(海南)有限公司 | 一种醋酸巴多昔芬胶囊及其制备方法 |
| CN107810001A (zh) | 2015-06-18 | 2018-03-16 | 密特拉制药公司 | 含雌四醇的口腔分散片剂 |
| CN107787224A (zh) | 2015-06-18 | 2018-03-09 | 密特拉制药公司 | 含雌四醇组分的口腔分散剂量单位 |
| PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
| CA2988362C (en) | 2015-06-18 | 2022-07-19 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| KR101893110B1 (ko) * | 2016-07-27 | 2018-08-31 | 삼일제약 주식회사 | 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제 |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| CN111067907A (zh) * | 2018-10-18 | 2020-04-28 | 常州大学 | 孕激素在抑制血管内皮生长因子表达中的应用 |
| KR102372271B1 (ko) * | 2020-01-03 | 2022-03-10 | 주식회사 서흥 | 천연 소재에 기반한 정제 조성물 및 정제 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022040896A1 (en) * | 2020-08-25 | 2022-03-03 | Abbvie Inc. | System and method of multi-drug delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2565115A (en) * | 1948-10-28 | 1951-08-21 | Squibb & Sons Inc | Method of obtaining a conjugated estrogen preparation |
| US2720483A (en) * | 1951-02-21 | 1955-10-11 | Olin Mathieson | Method of obtaining a conjugatedestrogen preparation |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| PE20060245A1 (es) * | 2004-06-07 | 2006-05-03 | Wyeth Corp | Recubrimientos de azucar y metodos para la fabricacion de los mismos |
| KR20080031037A (ko) * | 2005-06-29 | 2008-04-07 | 와이어쓰 | 결합형 에스트로겐과 바제독시펜의 제형 |
| BRPI0719675A2 (pt) * | 2006-11-29 | 2013-12-24 | Wyeth Corp | Comprimido com bicamada de estrogênio/serm e estrogênio/progestina |
-
2008
- 2008-01-11 MX MX2009007254A patent/MX2009007254A/es not_active Application Discontinuation
- 2008-01-11 KR KR1020097016863A patent/KR20090104862A/ko not_active Withdrawn
- 2008-01-11 RU RU2009125413/15A patent/RU2009125413A/ru not_active Application Discontinuation
- 2008-01-11 PE PE2008000126A patent/PE20081632A1/es not_active Application Discontinuation
- 2008-01-11 TW TW097101166A patent/TW200836773A/zh unknown
- 2008-01-11 AR ARP080100140A patent/AR064875A1/es unknown
- 2008-01-11 US US12/013,109 patent/US20080175908A1/en not_active Abandoned
- 2008-01-11 WO PCT/US2008/050899 patent/WO2008089087A2/en not_active Ceased
- 2008-01-11 JP JP2009545710A patent/JP2010515758A/ja active Pending
- 2008-01-11 CN CN200880007862A patent/CN101631536A/zh active Pending
- 2008-01-11 CL CL200800095A patent/CL2008000095A1/es unknown
- 2008-01-11 BR BRPI0806543-8A2A patent/BRPI0806543A2/pt not_active IP Right Cessation
- 2008-01-11 AU AU2008206476A patent/AU2008206476A1/en not_active Abandoned
- 2008-01-11 EP EP08727602A patent/EP2117518A2/en not_active Withdrawn
-
2009
- 2009-07-02 IL IL199656A patent/IL199656A0/en unknown
- 2009-07-08 CO CO09070672A patent/CO6210806A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009125413A (ru) | 2011-02-20 |
| CL2008000095A1 (es) | 2008-05-16 |
| BRPI0806543A2 (pt) | 2014-04-22 |
| MX2009007254A (es) | 2009-08-12 |
| CO6210806A2 (es) | 2010-10-20 |
| WO2008089087A2 (en) | 2008-07-24 |
| US20080175908A1 (en) | 2008-07-24 |
| AR064875A1 (es) | 2009-04-29 |
| KR20090104862A (ko) | 2009-10-06 |
| TW200836773A (en) | 2008-09-16 |
| AU2008206476A1 (en) | 2008-07-24 |
| WO2008089087A3 (en) | 2009-06-25 |
| JP2010515758A (ja) | 2010-05-13 |
| CN101631536A (zh) | 2010-01-20 |
| IL199656A0 (en) | 2010-04-15 |
| EP2117518A2 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081632A1 (es) | Composiciones de tableta en tableta | |
| PE20081301A1 (es) | Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina | |
| PE20061449A1 (es) | Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion | |
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| PE20141638A1 (es) | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato | |
| WO2011084593A3 (en) | Abuse-resistant formulations | |
| EP2512516A4 (en) | INJECTABLE POLYMERIC COMPOSITION FOR USE AS A CELL-RELATED CARRIER | |
| IL273300B1 (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| PH12012502159A1 (en) | Pharmaceutical compositions and methods of making same | |
| ES2530681T3 (es) | Composiciones farmacéuticas flotantes de liberación controlada | |
| PE20121498A1 (es) | Composiciones oftalmicas no irritantes de povidona-yodo | |
| PE20080273A1 (es) | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico | |
| MY156383A (en) | Pharmaceutical compositions | |
| CA2929865C (en) | Sprayable topical carrier and composition comprising phosphatidylcholine | |
| NZ602010A (en) | Improved glucocorticoid therapy | |
| MY163369A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yi) -1h-benzimidazol-2-y1]-1h-quinolin-2-one lactate monohydrate | |
| BR112013026965A2 (pt) | método para inibir micro-organismos prejudiciais e composição formadora de barreira para os mesmos | |
| WO2015092811A3 (en) | Oral films | |
| UY30461A1 (es) | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. | |
| PE20091160A1 (es) | Recubrimiento de tabletas farmaceuticas y/o nutraceuticas y/o veterinarias | |
| MX2008010879A (es) | Composiciones farmaceuticas de sodio de fluvastatina. | |
| PE20070188A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| NZ729628A (en) | Methods for the treatment of peri-implantitis | |
| PE20120990A1 (es) | Formulaciones de alisquireno e hidroclorotiazida | |
| EP3978027A4 (en) | PHYSIOLOGICALLY ACTIVE SUBSTANCE LINKED TO A BIOTIN FRACTION, AND COMPOSITION FOR ORAL ADMINISTRATION COMPRISING IT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |